Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28284867 | 0.96 | P2RX7 (0.39) | P2RX7MAPK1NR3C2TSHRMMP1 | |
| SCHEMBL10304837 | 0.83 | TNKS2 (0.45) | MAPK1MAPTAGXTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12656543 | 0.82 | NR3C2 (0.41) | P2RX7MAPK1NR3C2TSHRMMP1 | |
| SCHEMBL18361630 | 0.81 | P2RX7 (0.42) | P2RX7MAPK1NR3C2MMP1MAPT | |
| SCHEMBL8240380 | 0.81 | SLC6A4 (0.40) | P2RX7MAPK1TSHRMAPTPKM | |
| Ammonia Solution, Strong SCHEMBL6192622 | 0.80 | NR3C2 (0.40) | P2RX7MAPK1NR3C2TSHRMMP1 | |
| SCHEMBL3667517 | 0.80 | IDO1 (0.40) | MAPK1MAPTPKMIDO1AGXT | |
| SCHEMBL12446733 | 0.80 | KDM4E (0.45) | IDO1AGXTMAOBALDH1A1 | |
| SCHEMBL13849235 | 0.80 | PTGS2 (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL14533298 | 0.79 | P2RX7 (0.37) | P2RX7NR3C2MMP1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2023115142-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022268119-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3608325-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| WO-2022115620-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022078462-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NUVATION BIO INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11241448-B2 | Methods for cancer therapy | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210177871-A1 | METHODS FOR CANCER THERAPY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-17 | — | — | US | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2055710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | P2RX7 2998/4885MAPK1 3848/4885NR3C2 2393/4885 |
| US-11254670-B2 | 1,8-naphthyridinone compounds and uses thereof | NME1, ADORA2A, GPR68 | P2RX7 165/4885MAPK1 510/4885NR3C2 719/4885 |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | P2RX7 100/4885MAPK1 1942/4885NR3C2 953/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | P2RX7 473/4885MAPK1 3458/4885NR3C2 3135/4885 |
| US-11241448-B2 | Methods for cancer therapy | TP53, BRCA1, PSMA1 | P2RX7 4623/4885MAPK1 1529/4885NR3C2 832/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | P2RX7 671/4885MAPK1 3695/4885NR3C2 2205/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | P2RX7 3544/4885MAPK1 2608/4885NR3C2 2705/4885 |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | P2RX7 165/4885MAPK1 510/4885NR3C2 719/4885 |
| US-20210177871-A1 | METHODS FOR CANCER THERAPY | TP53, BRCA1, PSMA1 | P2RX7 4623/4885MAPK1 1529/4885NR3C2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.